NDA 021711 · Lantheus Medcl
Ablavar
Gadofosveset Trisodium · Intravenous
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 7, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Dec 22, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 2008 Original approval · Type 1 - New Molecular Entity NovelSummary ReviewReviewOther Important Information from FDA
2 products under this application
- ABLAVAR · GADOFOSVESET TRISODIUM 3660MG/15ML (244MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- ABLAVAR · GADOFOSVESET TRISODIUM 2440MG/10ML (244MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadofosveset Trisodium" as an intervention, any sponsor and status, largest first.
Bachir TaouliAcademic, hospital or other
NCT01600105 · 276 participants · Start Oct 2010 · Primary completion Jul 31, 2017
Drug: Perfusion MRI · For: Chronic Liver Disease
Sites: New York, New York
- Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00296855 · 261 participants · Start Feb 2006
Drug: Vasovist (BAY86-5283, MS-325) · For: Peripheral Vascular Diseases
Sites: Buenos Aires, Argentina; Lornas de Zamora, Argentina; Sankt Pölten, Austria · 26 sites in all
Stanford UniversityAcademic, hospital or other
NCT00375830 · 114 participants · Start Jan 2006 · Primary completion Apr 17, 2017
Drug: 99mTc-methyl diphosphonate; 18F-Fludeoxyglucose (18F-FDG) and 4 more · For: Cancer
Sites: Stanford, California
- Nodal Staging in Breast Cancer With MRLTerminated
Maastricht University Medical CenterAcademic, hospital or other
NCT01609920 · 97 participants · Start May 2012 · Primary completion May 2016
Drug: Gadofosveset enhanced MRL of axillary lymph nodes · For: Breast Neoplasms
Sites: Maastricht, Netherlands
- Renal MRA Crossover Study Comparing Multihance to Another Contrast AgentPivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT00415805 · 39 participants · Start Dec 2006 · Primary completion Dec 2008
Drug: Multihance; vasovist · For: Steno-occlusive Disease
Sites: Milan, Italy
Duke UniversityAcademic, hospital or other
NCT01431300 · 30 participants · Start Aug 2011 · Primary completion Jul 2012
Drug: gadofosveset · For: Healthy
Sites: Durham, North Carolina
- Imaging of Totally Blocked ArteriesCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00459446 · 20 participants · Start Apr 5, 2007 · Primary completion Nov 25, 2008
Drug: MS-325 Injection (Gadofosveset Trisodium) · For: Atherosclerosis; Peripheral Artery Disease; Intermittent Claudication and 1 more
Sites: Bethesda, Maryland
Paul FinnAcademic, hospital or other
NCT02752191 · 17 participants · Start Apr 2016 · Primary completion Dec 19, 2018
Drug: ferumoxytol; gadofosveset · For: Pediatric Congenital Heart Disease
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging.
Ahlman MA, Raman FS, Pang J, et al. · BMC Cardiovasc Disord 2016 · Clinical Trial, Comparative Study
- MR angiographic follow-up of intracranial aneurysms treated with detachable coils: evaluation of a blood-pool contrast medium.
Kau T, Gasser J, Celedin S, et al. · AJNR Am J Neuroradiol 2009 · Clinical Trial
- Gadofosveset trisodium in the investigation of focal liver lesions in noncirrhotic liver: Early experience.
Milot L, Haider M, Foster L, et al. · J Magn Reson Imaging 2012 · Controlled Clinical Trial
- Dose response of the intravascular contrast agent gadofosveset trisodium in MR perfusion imaging of the myocardium using a quantitative evaluation.
Niedermayer S, Sourbron S, Prompona M, et al. · Int J Cardiovasc Imaging 2013 · Randomized Controlled Trial
- A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis.
Mani V, Alie N, Ramachandran S, et al. · J Vis Exp 2015 · Multicenter Study, Randomized Controlled Trial
- Technique and protocols for cardiothoracic time-resolved contrast-enhanced magnetic resonance angiography sequences: a systematic review.
Zanardo M, Sardanelli F, Rainford L, et al. · Clin Radiol 2021 · Systematic Review
Sponsor: Lantheus Medcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.